BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7518341)

  • 1. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
    Pollack A; Zagars GK; Kavadi VS
    Cancer; 1994 Jul; 74(2):670-8. PubMed ID: 7518341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.
    Pollack A; Zagars GK; el-Naggar AK; Terry NH
    Urology; 1994 Nov; 44(5):711-8. PubMed ID: 7526527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer.
    Zagars GK; Pollack A
    Radiother Oncol; 1997 Sep; 44(3):213-21. PubMed ID: 9380819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.
    Zagars GK; von Eschenbach AC
    Cancer; 1993 Jul; 72(2):538-48. PubMed ID: 7686443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
    Zelefsky MJ; Ben-Porat L; Scher HI; Chan HM; Fearn PA; Fuks ZY; Leibel SA; Venkatraman ES
    J Clin Oncol; 2005 Feb; 23(4):826-31. PubMed ID: 15681527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer.
    Zagars GK; Pollack A
    Cancer; 1993 Aug; 72(3):832-42. PubMed ID: 7687516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
    Zagars GK; Pollack A
    Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy.
    Zagars GK
    Int J Radiat Oncol Biol Phys; 1992; 23(1):47-53. PubMed ID: 1374065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.
    Zagars GK; Pollack A; von Eschenbach AC
    Cancer; 1997 Apr; 79(7):1370-80. PubMed ID: 9083160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
    Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
    Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PSA doubling time in prostate cancer relapsed after endocrine therapy].
    Nakata S; Takahashi H; Takezawa Y; Kobayashi M; Matumoto K; Kosaku N; Kawashima K
    Nihon Hinyokika Gakkai Zasshi; 2000; 91(7-8):584-8. PubMed ID: 10965743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.
    Chauvet B; FĂ©lix-Faure C; Lupsascka N; Fijuth J; Brewer Y; Davin JL; Kirscher S; Reboul F
    J Clin Oncol; 1994 Jul; 12(7):1402-7. PubMed ID: 7517443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy.
    Gauwitz MD; Pollack A; el-Naggar AK; Terry NH; von Eschenbach AC; Zagars GK
    Int J Radiat Oncol Biol Phys; 1994 Mar; 28(4):821-8. PubMed ID: 8138434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer.
    Pollack A; Zagars GK; Kopplin S
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):13-20. PubMed ID: 7536720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.
    Sartor CI; Strawderman MH; Lin XH; Kish KE; McLaughlin PW; Sandler HM
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(5):941-7. PubMed ID: 9276358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
    J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
    Lee WR; Hanks GE; Hanlon A
    J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy.
    Pollack A; Zagars GK; el-Naggar AK; Gauwitz MD; Terry NH
    Cancer; 1994 Apr; 73(7):1895-903. PubMed ID: 7511039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate.
    Zagars GK
    Int J Radiat Oncol Biol Phys; 1993 Sep; 27(1):39-45. PubMed ID: 7690017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.